LivaNova's OSPREY Sleep Apnea Trail on aura6000 Meets Primary Endpoint

Zacks11-18

LivaNova’s LIVN OSPREY trial, evaluating the aura6000 nerve stimulation system for obstructive sleep apnea (OSA), has delivered promising results. By meeting primary safety and efficacy endpoints, the...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484753686?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GmVc8.ZtfGjPFG_U83F8fA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e34d884fa2c79bf8b02903b1effd4c0b","is_english":true,"pubTime":"2024-11-18 20:42","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2484753686","market":"us","top_or_hot":-1,"title":"LivaNova's OSPREY Sleep Apnea Trail on aura6000 Meets Primary Endpoint","media":"Zacks","content":"<div>\n<p>LivaNova’s LIVN OSPREY trial, evaluating the aura6000 nerve stimulation system for obstructive sleep apnea (OSA), has delivered promising results. By meeting primary safety and efficacy endpoints, the...</p>\n\n<a href=\"https://finance.yahoo.com/news/livanovas-osprey-sleep-apnea-trail-124200622.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LivaNova's OSPREY Sleep Apnea Trail on aura6000 Meets Primary Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLivaNova's OSPREY Sleep Apnea Trail on aura6000 Meets Primary Endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-18 20:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/livanovas-osprey-sleep-apnea-trail-124200622.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>LivaNova’s LIVN OSPREY trial, evaluating the aura6000 nerve stimulation system for obstructive sleep apnea (OSA), has delivered promising results. By meeting primary safety and efficacy endpoints, the...</p>\n\n<a href=\"https://finance.yahoo.com/news/livanovas-osprey-sleep-apnea-trail-124200622.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4167","symbol_name":"医疗保健技术","start_time":0,"source_url":"https://finance.yahoo.com/news/livanovas-osprey-sleep-apnea-trail-124200622.html","article_id":"2484753686","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GmVc8.ZtfGjPFG_U83F8fA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e34d884fa2c79bf8b02903b1effd4c0b"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484753686","pubTimestamp":1731933720,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"LivaNova’s LIVN OSPREY trial, evaluating the aura6000 nerve stimulation system for obstructive sleep apnea , has delivered promising results. By meeting primary safety and efficacy endpoints, the study marks a significant step forward for targeted hypoglossal nerve stimulation as a viable treatment for moderate to severe OSA.The trial’s primary endpoint focused on responder rates, defined as patients achieving at least a 50% reduction in apnea-hypopnea index , resulting in an AHI below 20. The treatment group showed significantly higher responder rates than the sham group, meeting the pre-specified statistical threshold of p<0.025. This achievement not only underscores the therapy’s clinical relevance but also strengthens the case for FDA premarket approval.LivaNova plans to submit the OSPREY trial data to the FDA as part of its premarket approval application following the completion of the six-month data assessment. The robust safety and efficacy data provide a strong foundation for r","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4167":"医疗保健技术","BK4082":"医疗保健设备","LIVN":"LivaNova PLC","LU0240877869.USD":"SCHRODER ISF GLOBAL SMALL COMPANIES \"A\" ACC","BK4097":"系统软件","ANGO":"阿吉奥动态","AHI":"ADVANCED HEALTH INTELLIGENCE LTD SPON ADS EACH REP 7 ORD SHS","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","MASI":"麦斯莫医疗","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","LU0240878834.USD":"SCHRODER ISF GLOBAL SMALL COMPANIES \"A\" (USD) INC AV","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","GMED":"Globus Medical Inc","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC"},"translate_title":"LivaNova在aura6000上的OSPREY睡眠呼吸暂停试验达到主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AHI":1,"ANGO":1,"GMED":1,"MASI":1,"OSA":1,"LIVN":0.9},"content_text":"LivaNova’s LIVN OSPREY trial, evaluating the aura6000 nerve stimulation system for obstructive sleep apnea (OSA), has delivered promising results. By meeting primary safety and efficacy endpoints, the study marks a significant step forward for targeted hypoglossal nerve stimulation as a viable treatment for moderate to severe OSA.\nThe trial’s primary endpoint focused on responder rates, defined as patients achieving at least a 50% reduction in apnea-hypopnea index (AHI), resulting in an AHI below 20. The treatment group showed significantly higher responder rates than the sham group, meeting the pre-specified statistical threshold of p<0.025. This achievement not only underscores the therapy’s clinical relevance but also strengthens the case for FDA premarket approval.\nThe company’s shares have risen 0.7% so far this year compared with the industry’s growth of 2.7%. The S&P 500 Index has gained 23.4% during the same period.\nImage Source: Zacks Investment Research\nStudy Data in Details\nThe OSPREY trial focused on measuring AHI and oxygen desaturation index (ODI) as secondary endpoints, both critical metrics in assessing OSA severity. The data from the trial showed that using aura6000 led to a 66.2% reduction in AHI, with the median falling from 34.3 at baseline to 11.6 at six months. ODI reduced 63.3%, with the median dropping from 34.9 at baseline to 12.8 at six months. These reductions represent statistically significant improvements, highlighting the efficacy of the aura6000 system in managing OSA.\nThe OSPREY trial reported no serious adverse device-related or procedure-related events, emphasizing the aura6000 system’s favorable safety profile. This result bolsters confidence in the device's potential for widespread clinical use.\nThe OSPREY trial will continue to collect 12-month data, with results expected in early 2025. These findings will offer valuable insights into the therapy's sustained efficacy and safety. A favorable long-term profile could further solidify the device’s role in the OSA treatment landscape.\nFDA Submission and Path to Approval\nLivaNova plans to submit the OSPREY trial data to the FDA as part of its premarket approval application following the completion of the six-month data assessment. The robust safety and efficacy data provide a strong foundation for regulatory review. Approval of the aura6000 system would position it as a novel option for patients who struggle with conventional OSA treatments such as positive airway pressure (PAP).\nOSA affects millions of adults worldwide, with significant implications for cardiovascular health, cognitive function and quality of life. The aura6000 system provides an alternative for patients who cannot tolerate or benefit from PAP. With significant reductions in AHI and ODI demonstrated in just six months, the device holds promise for improving long-term outcomes and adherence.\nFavorable Industry Prospects for LIVN\nPer a report by Markets and Markets, the global sleep apnea device market was valued at approximately$6.5 billion in 2023 and is anticipated to reach $9.3 billion by 2029 at a CAGR of 7.3%.\nFactors like the expansion of reimbursement coverage and the growing adoption of telemedicine and artificial intelligence are likely to be the key drivers for sleep apnea device demand.\nGiven the market potential, an approval for Auro6000 next year is likely to boost LIVN’s business prospects.\n\nLivaNova PLC Price\n\nLivaNova PLC price | LivaNova PLC Quote\n\nLIVN’s Zacks Rank & Other Stocks to Consider\nLivaNova currently carries a Zacks Rank #2 (Buy).\nSome other top-ranked stocks from the medical industry are Masimo MASI, AngioDynamics ANGO and Globus Medical GMED.\nMasimo, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated growth rate of 10.4% for 2025. You can seethe complete list of today’s Zacks #1 Rank stocks here.\nMASI’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 17.10%. Masimo’s shares have risen 37.2% year to date compared with the industry’s 6.7% growth.\nAngioDynamics, carrying a Zacks Rank #2 at present, has an estimated growth rate of 38.2% for 2025. ANGO’s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 31.71%.\nAngioDynamics’ shares have lost 8.9% year to date against the industry’s 6.7% growth.\nGlobus Medical, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.7%. GMED’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.1%. Its shares have risen 56.5% year to date compared with the industry’s 6.7% growth.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nAngioDynamics, Inc. (ANGO) : Free Stock Analysis Report\nMasimo Corporation (MASI) : Free Stock Analysis Report\nGlobus Medical, Inc. (GMED) : Free Stock Analysis Report\nLivaNova PLC (LIVN) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484753686"}